Clinical Study Results Sanofi Pharma, including Sanofi Genzyme



Information about sponsored clinical trials and result information are provided for informational purposes only and are not intended to promote any product or use. Clinical study results are intended to report the results of the study that were known at the time of the study's completion. The results therefore do not provide a comprehensive and current review of the safety and efficacy of any drug based upon all information available. Physicians and patients should refer to the current approved product labeling for information on approved indications in their country.
This information is not intended to replace the advice of a health care professional. Only a physician can determine if a specific medicine is the correct or best treatment option for a particular patient. If you have questions, please consult a health care professional.

A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z

Clinical study results Sanofi pharma, including Sanofi Genzyme – Letter P

Generic Name Trade Name Condition Study Code Study Name Access to study Access to results
PAN PI3K INHIBITOR Not marketed Endometrial Neoplasms ARD11436 NA EudraCT: 2009-016707-30
PAN PI3K INHIBITOR Not marketed Breast Neoplasms ARD11437 NA NCT01082068
PAN PI3K INHIBITOR Not marketed Breast Neoplasms ARD11439 NA EudraCT: 2009-016862-10
PAN PI3K INHIBITOR Not marketed Solid Tumors TCD11742 NA NCT01357330
PAN PI3K INHIBITOR Not marketed Neoplasms TED12863 NA NCT01943838
PAN PI3K INHIBITOR Not marketed Solid Tumors TED11883 NA NCT01392924
PAN PI3K AND MTOR INHIBITOR Not marketed Lymphoma or Leukemia ARD12130 NA EudraCT: 2011-001616-57
PAN PI3K AND MTOR INHIBITOR Not marketed Indolent Lymphoma TCD12012 NA NCT01410513
PAN PI3K AND MTOR INHIBITOR Not marketed Glioblastoma TED11605 NA NCT01240460
PAN PI3K AND MTOR INHIBITOR Not marketed Neoplasms TED12471 NA NCT01596270
PARACETAMOL Doliprane Pain PARAC_L_00859 NA NCT00434681
PHOSPHATIDYL CHOLINE Essentiale Liver Disease CHOLIL06301 EPLID NCT02517385
PI3K-B INHIBITOR Not marketed Solid Tumors, Lymphoma TCD12739 NA NCT01673737
PLERIXAFOR Mozobil Non-Hodgkin's Lymphoma ACT12781 NA NCT02221492
PLERIXAFOR Mozobil Multiple Myeloma ACT13710 NA NCT02221479
PLERIXAFOR Not marketed Renal Impairment AMD31001101 NA NCT00445302
PLERIXAFOR Mozobil Multiple Myeloma or Non-Hodgkin's Lyjmphoma AMD3100-2104 NA NCT00322387
PLERIXAFOR Mozobil Multiple Myeloma or Non-Hodgkin's Lyjmphoma AMD3100-2105 NA NCT00322491
PLERIXAFOR Not marketed Hodgkin's Disease AMD3100-2106 NA NCT00396201
PLERIXAFOR Mozobil Multiple Myeloma AMD3100-2108 NA NCT00396383
PLERIXAFOR Mozobil Multiple Myeloma or Non-Hodgkin's Lyjmphoma AMD3100-2109 NA NCT00395967
PLERIXAFOR Not marketed Transplantation AMD31002112 NA NCT00396331
PLERIXAFOR Mozobil Non-Hodgkin's Lymphoma or Hodgkin's Disease AMD31002113 NA NCT00444912
PLERIXAFOR Mozobil Non-Hodgkin's Lymphoma AMD31003101 NA NCT00103610
PLERIXAFOR Mozobil Multiple Myeloma AMD31003102 NA NCT00103662
PLERIXAFOR Mozobil Multiple Myeloma or Non-Hodgkin's Lyjmphoma AMD3100C201 NA NCT00396266
PLERIXAFOR Mozobil Multiple Myeloma or Non-Hodgkin's Lyjmphoma AMD3100EU21 NA NCT00322842
PLERIXAFOR Not marketed Solid Tumors MOZ15609-DFI12860 MOZAIC EudraCT: 2010-019340-40
PLERIXAFOR Mozobil Non-Hodgkin's Lymphoma EFC12482 NA NCT01767714
PLERIXAFOR Mozobil Non-Hodgkin's Lymphoma MOZ11809 NA NCT01164475
PRISTINAMYCIN Pyostacin Infection PRIST_L_01683 NA NCT00393744


References:
*These study results were previously posted on GenzymeClinicalResearch.com
**This link replaces the same summary that was previously posted